{"ID variables": ["\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Gender of participant\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Subject IDs, Consents, and Subject Aliases\\Subject ID\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\SEQUENCING CENTER\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Subject IDs, Consents, and Subject Aliases\\Subject source ID\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Subject IDs, Consents, and Subject Aliases\\Subject source\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Other IDs\\De-identified Subject ID\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\Analyte Type\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\Study Name\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\De-identified Sample ID\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Affection Status\\Case control status of the subject for atrial fibrillation (AF)\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Subject IDs, Consents, and Subject Aliases\\Consent group as determined by DAC\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\TOPMed Project\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Subject Sample Mapping and Sample Use\\Sample ID\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\Body site where sample was collected\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\Funding Source\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Sociodemography\\Race of participant\\", "\\_Consents\\Short Study Accession with Consent Code\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\AF status\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sociodemography and Administration\\Subject Sample Mapping and Sample Use\\Subject ID\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\Tumor status\\"], "phenotypic variables": ["Patient ID", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Apo A1\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Apo B\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Baseline blood draw at least 8 hours after last meal\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\CRP(Denka)\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Creatinine\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Diastolic blood pressure\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Fibrinogen\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\HDL cholesterol in mg/dl at baseline\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\HbA1c\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Homocysteine\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\ICAM\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\LDL cholesterol in mg/dl at baseline, direct measure\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Lp(a)\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 10\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 1\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 2\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 3\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 4\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 5\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 6\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 7\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 8\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Principal Components\\Principal component 9\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Systolic blood pressure\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Total cholesterol at baseline\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Laboratory Measurements\\Triglycerides in mg/dl at baseline\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Alcohol use\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Cholesterol lowering medication at baseline\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Exercise\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Lifestyle and Environment\\Smoking status\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at AF diagnosis\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at enrollment\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at menarche\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Age at menopause\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Body mass index\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Diabetes at baseline\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Height\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Metabolic syndrome\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Uterine fibroids\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Waist/hip ratio\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Physical Observations\\Weight\\", "\\NHLBI TOPMed: Novel Risk Factors for the Development of Atrial Fibrillation in Women\\Sample Attributes\\TOPMed Phase\\"]}